EGFR and non-small cell lung carcinoma: A meta-analysis on data from randomized trials of ICIs in NSCLC also found that no significant improvement in OS in the EGFR mutant subgroup treated with ICIs, although prolonged OS was observed in whole study populations and in the EGFR wild-type subgroup when compared with patients treated with docetaxel [86].